| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 07/21/2005 | WO2005065674A1 Pharmaceutical composition of 2-(4-isobutylphenyl) propionic acid |
| 07/21/2005 | WO2005065666A1 Us of a pkc-delta inhibitor for the inhibition of metastatic melanoma |
| 07/21/2005 | WO2005065659A1 Consumer customized dosage forms |
| 07/21/2005 | WO2005065651A1 Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid prepared from a unit dose suspension |
| 07/21/2005 | WO2005065650A2 Aerosol formulations comprising a carboxylic acid surfactant |
| 07/21/2005 | WO2005065649A1 Inhalant formulation containing sulfoalkyl ether ϝ-cyclodextrin and corticosteroid |
| 07/21/2005 | WO2005065435A2 Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid |
| 07/21/2005 | WO2005065383A2 Oxidative reductive potential water solution, processes for producing same and methods of using the same |
| 07/21/2005 | WO2005065282A2 Remote magnetically induced treatment of cancer |
| 07/21/2005 | WO2005065121A2 Methods and compositions for the production of monoclonal antibodies |
| 07/21/2005 | WO2005046722A3 Carbohydrate antigen-nanoparticle conjugates and uses thereof as antimetastatic agents in treating cancer |
| 07/21/2005 | WO2005037294A8 Compositions for controlling parasites comprising a combination of abamectin and ivermectin |
| 07/21/2005 | WO2005030170A3 Controlled rupture of furtive liposomes |
| 07/21/2005 | WO2005014823A3 Targeted carrier fusions for delivery of chemotherapeutic agents |
| 07/21/2005 | WO2005007819A3 Charge-dynamic polymers and delivery of anionic compounds |
| 07/21/2005 | WO2004087045A3 Devices, methods, and compositions to prevent restenosis |
| 07/21/2005 | WO2004030617A3 Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof |
| 07/21/2005 | WO2003057160A8 Compositions and methods for the diagnosis and treatment of tumor |
| 07/21/2005 | WO2002000207A9 The controlled release preparation of insulin and its method |
| 07/21/2005 | US20050159822 Particulate acellular tissue matrix |
| 07/21/2005 | US20050159695 Comprises antimicrobial substances, pain relievers, protease inhibitors, kallikrein, and tissue-plasminogen activator |
| 07/21/2005 | US20050159556 Zwitterionic polymers |
| 07/21/2005 | US20050159544 biocompatible, synthetic, and nonimmunogenic, crosslinkable polymer compositions of a first synthetic polymer containing multiple nucleophilic groups and a second synthetic polymer containing multiple electrophilic groups; use as implant coatings, preventing surgical adhesions |
| 07/21/2005 | US20050159492 Enhancing bioavailability of oral immediate release tablets for low solubility medicants; respiratory inflammatory disorders |
| 07/21/2005 | US20050159441 Active ingredient and solvent can be stored separately until apparatus is used in a nebuliser; propellant-free; active ingredient is present in highly-concentrated form for storage purposes; inhalers |
| 07/21/2005 | US20050159439 Management of postoperative pain |
| 07/21/2005 | US20050159395 Topical applying to skins; skin disorders; anticarcinogenic agents |
| 07/21/2005 | US20050159382 For cancer such as prostate cancer |
| 07/21/2005 | US20050159381 Cancer, tumor angiogenesis, diabetic retinopathy, inflammatory conditions such as arthritis, osteoporosis, wound healing |
| 07/21/2005 | US20050159380 used to modulate the expression of Angiopoietin genes |
| 07/21/2005 | US20050159379 RNA interference mediated inhibition of gastric inhibitory polypeptide (GIP) and gastric inhibitory polypeptide receptor (GIPR) gene expression using short interfering nucleic acid (siNA) |
| 07/21/2005 | US20050159378 For proliferative diseases and disorders such as multiple drug resistant cancers, such as leukemias including acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML), Acute lymphocytic leukemia (ALL) , lymphoma, prostate cancer, carcinoma |
| 07/21/2005 | US20050159376 RNA interference mediated inhibition 5-alpha reductase and androgen receptor gene expression using short interfering nucleic acid (siNA) |
| 07/21/2005 | US20050159360 Improved bioavailability |
| 07/21/2005 | US20050159353 Site-specific preparation of polyethylence glycol-GRF conjugates |
| 07/21/2005 | US20050159344 Forming a carboxy-saccharide derivative of the glycopeptide antibiotic that has a substituent containing a dicarboxylic acid in which one of the carboxylic acid groups is coupled with a saccharide |
| 07/21/2005 | US20050159335 Pharmaceutical administration form for peptides, process for its preparation, and use |
| 07/21/2005 | US20050158828 Preparing immunoglobulin dimer for use in prevention and treatment of B cell lymphoma and chronic lymphocytic leukemia; immunotherapeutics |
| 07/21/2005 | US20050158780 Nucleic acid ligands to the prostate specific membrane antigen |
| 07/21/2005 | US20050158735 Double stranded RNA sequences for use in prevention and treatment of restenosis and cell proliferative disorders; gene expression inhibition |
| 07/21/2005 | US20050158734 Alleles corresponding to various diet-associated phenotypes |
| 07/21/2005 | US20050158408 Dried forms of aqueous solubilized bile acid dosage formulation: preparation and uses thereof |
| 07/21/2005 | US20050158407 Antipyrotic and method of manufacturing the same |
| 07/21/2005 | US20050158396 Comprises extracts selected from of Vaccinium myrtillus, Trifolium pratense, Vitis vinifera and Thea vinensis; group consisting of anthocyanosides, isoflavone glucosides and polyphenols; and a co-active component selected from the group consisting tocopherol, ascorbic acid |
| 07/21/2005 | US20050158394 Oral administration of solid dosage forms; multiple unit dosing device comprising a housing and an actuator |
| 07/21/2005 | US20050158387 Olopatadine formulations for topical administration |
| 07/21/2005 | US20050158386 Process for producing a pharmaceutical solid preparation containing a poorly soluble drug |
| 07/21/2005 | US20050158379 Minimization of drug oxidation in drug irradiated excipients formulations |
| 07/21/2005 | US20050158375 Improved residence time in the blood and migration into tumor cells; reduced accumulation in the heart |
| 07/21/2005 | US20050158374 Compositions and dosage forms for enhanced absorption of metformin |
| 07/21/2005 | US20050158373 Method and carrier complexes for delivering molecules to cells |
| 07/21/2005 | US20050158371 Ointment, cream containing SMP-114 or leflunomide; N-(4-trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide; antiinflammatory or antirheumatic |
| 07/21/2005 | US20050158370 Charge-balanced chemoselective linkers |
| 07/21/2005 | US20050158348 Eutectic mixture of camphor, menthol, thymol and similar compounds is a powerful solvent for non-steroidal anti-inflammatory drugs; transdermal drug delivery of e.g. indomethacin, diclofenac, or ketoprofen |
| 07/21/2005 | US20050158330 water in oil in water (w/o/w) emulsion; polyethylene glycol outer aqueous phase; low viscosity for easier injection; storage stability; less topical response at the injection site; high immunological effect |
| 07/21/2005 | US20050158322 Single chain Fv antibody fragments; for diagnosis/prognosis of human colorectal tumors |
| 07/21/2005 | US20050158303 Antibody; stability, reduced viscosity, turbidity, istonic, stability; administering under skins |
| 07/21/2005 | US20050158296 administering to a patient suffering from a lysosomal storage disease a P97 conjugated with an enzyme which is capable of transportation into the lysosomes of cells on either sides of the blood brain barrier |
| 07/21/2005 | US20050158276 Bordetella pertussis antigen consisting lipopolysaccharide, pertusis toxin, filamentous hemagglutinin, pertactin or abosrbed to alum; interleukin-12 ; enhances cell-mediated immunity in a host |
| 07/21/2005 | US20050158273 Soluble, degradable polyethylene glycol) derivatives for controllable release of bound molecules into solution |
| 07/21/2005 | US20050158271 Copolymer of hydrophilic monomers and hydrophobic monomers which have a pendant hydrotropic moiety; hydrotropic polymer micelle has nanometer scale size, can deliver poorly soluble drugs, Paclitaxel, to the body |
| 07/21/2005 | US20050158259 Red light-filtering dye andhamamelis, Glycyrrhiza inflata, panthenol or camomile extract; treating sun-irritated skin |
| 07/21/2005 | US20050158253 Enzyme and an enzyme-anchor complex; degrades biofilm structures; complex acts as a bactericide |
| 07/21/2005 | US20050158250 Granulated composition of soluble, powdered insulin and a carrier of aggregated crystalline cellulose; increases a blood insulin concentration |
| 07/21/2005 | US20050158249 Therapeutic, prophylactic or diagnostic agent and biodegradable polymer; deposited after the first bifurcation of the lungs |
| 07/21/2005 | US20050158247 [Tris(hydroxymethyl) aminomethane] as a selective absorbefacient, a therapeutically effective amount of active nasal peptide, in an aqueous liquid diluent; administered through the nasal mucosa-lined-epithelium |
| 07/21/2005 | DE19901683B4 Analgetikum mit kontrollierter Wirkstofffreisetzung Analgesic with controlled release of active ingredient |
| 07/21/2005 | DE10024383B4 Mit toxischen Substanzen beladene dendritische Zellen With toxic substances loaded dendritic cells |
| 07/21/2005 | CA2553943A1 Oxidative reductive potential water solution, processes for producing same and methods of using the same |
| 07/21/2005 | CA2552909A1 Pharmaceuticals for topical application in animals |
| 07/21/2005 | CA2552641A1 Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid prepared from a unit dose suspension |
| 07/21/2005 | CA2552590A1 Interleukin-12 targeted to oncofoetal fibronectin |
| 07/21/2005 | CA2552251A1 Targeted immunogens |
| 07/21/2005 | CA2552188A1 Polypeptides and immunogenic conjugates capable of inducing antibodies against pathogens, and uses thereof |
| 07/21/2005 | CA2552139A1 Medicinal compositions and method for the preparation thereof |
| 07/21/2005 | CA2551913A1 Autoantibodies utilized as carrier agents for pharmaceutical compounds used in tumor imaging and cancer treatment |
| 07/21/2005 | CA2551896A1 Formulations of hydrophobic proteins in an immunogenic composition having improved tolerability |
| 07/21/2005 | CA2551826A1 Inhalant formulation containing sulfoalkyl ether .gamma.-cyclodextrin and corticosteroid |
| 07/21/2005 | CA2551749A1 Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid |
| 07/21/2005 | CA2551564A1 A simplified method to retrieve chitosan from acidic solutions thereof |
| 07/21/2005 | CA2551530A1 Intranasal administration of glucose-regulating peptides |
| 07/21/2005 | CA2551525A1 Pharmaceutical composition for thrombin peptide derivatives |
| 07/21/2005 | CA2548179A1 Methods and compositions for the production of monoclonal antibodies |
| 07/20/2005 | EP1555031A1 Angiogenesis inducer |
| 07/20/2005 | EP1555030A1 Sustained release preparation for treating coronary stenosis or obstruction |
| 07/20/2005 | EP1555023A2 Injectable buprenorphine microparticle compositions and their use |
| 07/20/2005 | EP1554936A1 Ketoprofen-supplemented animal feed and use thereof in the simultaneous treatment of a group of animals for processes which are accompanied by fever, inflammation and/or pain |
| 07/20/2005 | EP1554572A2 Compositions and methods for modulating blood-brain barrier transport |
| 07/20/2005 | EP1554316A1 Lignan complexes |
| 07/20/2005 | EP1554315A1 Water-soluble iron-carbohydrate complexes, production thereof, and medicaments containing said complexes |
| 07/20/2005 | EP1554306A2 Conjugates comprised of polymer and hiv gp41-derived peptides and their use in therapy |
| 07/20/2005 | EP1554242A1 Watersoluble prodrugs of propofol |
| 07/20/2005 | EP1553974A1 Pharmaceutical composition comprising carriers for products |
| 07/20/2005 | EP1553971A2 THERAPIES FOR RENAL FAILURE USING INTERFERON-b |
| 07/20/2005 | EP1553963A1 Novel agents that modulate eph receptor activity |
| 07/20/2005 | EP1553956A2 Formulation for lipophilic agents |
| 07/20/2005 | EP1553954A2 Dihydrate dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compostions thereof |
| 07/20/2005 | EP1553953A1 Method and composition containing latanoprost for treating ocular hypertension and glaucoma |
| 07/20/2005 | EP1553945A2 Nitroxide radioprotector formulations and methods of use |
| 07/20/2005 | EP1553940A1 Parenteral formulations containing a rapamycin hydroxyester |